Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020)

Akebia Therapeutics (AKBA) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $35.1 million in Q1 2020.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 806.04% year-over-year to $35.1 million in Q1 2020; TTM through Mar 2020 was $35.1 million, a 806.04% increase from a year earlier, with the FY2019 full-year figure at $109.4 million, down 8.42% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2020 stood at $35.1 million, down from $109.4 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for AKBA reached as high as $119.4 million in Q4 2018 and fell as low as $1.8 million in Q3 2019.
• Historically, Non-Current Deferred Tax Liability has averaged $45.4 million across 3 years, with a median of $19.5 million in 2019.
• Across the five-year window, Non-Current Deferred Tax Liability declined 8.42% in 2019 and surged 806.04% in 2020, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $119.4 million in 2018, then fell by 8.42% to $109.4 million in 2019, then tumbled by 67.9% to $35.1 million in 2020.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $35.1 million in Q1 2020, $109.4 million in Q4 2019, and $1.8 million in Q3 2019.